Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dexycu for postoperative inflammation after cataract surgery
CTR20212869Phase 3Completed
- Sponsor
- EyePoint Pharmaceuticals
- Start
- Nov 2021
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Injectable Hydrogels → Hydrogel Systems → Drug Delivery Systems
- Countries
- 1
01
Overview
A Phase 3 trial of IBI-10090 in post-operative inflammation, sponsored by EyePoint Pharmaceuticals. Started Nov 2021; status: completed.
02
Drugs
IBI-10090
03
Conditions
post-operative inflammation
Beyond the preview
Go deeper on CTR20212869.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20212869.